Minerva Neurosciences, Inc. (NERV)
| Market Cap | 40.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.92M |
| Shares Out | 42.72M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | 11.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 228,086 |
| Open | 0.910 |
| Previous Close | 0.873 |
| Day's Range | 0.880 - 0.970 |
| 52-Week Range | 0.832 - 3.750 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 7.00 (+646.1%) |
| Earnings Date | Nov 8, 2021 |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma C...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 646.11% from the latest price.
News
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET
Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as ...
WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
Management to Host Conference Call Management to Host Conference Call
Minerva Neurosciences Announces Promotion of Geoff Race to President
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. Re...
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commerci...
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates
Minerva Neurosciences (NERV) delivered earnings and revenue surprises of -47.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous ...
Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for
Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
Management to host conference call Management to host conference call
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centr...
Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centra...
Minerva Neurosciences (NERV) Enters Overbought Territory
Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Best Penny Stocks to Buy During a Market Correction? Check These 4 Out
Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?
Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May
Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Informat...
Minerva (NERV) Soars on Promising Schizophrenia Study Data
Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boos...
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, impr...
Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Sympto...
WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous s...
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021
Management to host conference call Management to host conference call
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock?
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc...
LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva...